Active Implants LLC
- Industry
- Medical Devices
- Founded Year
- 2004
- Headquarters
- Memphis, Tennessee, USA
- Employee Count
- 0
Key People
- Ted Davis - President and CEO
- Elliott Hershman, M.D. - Chief Medical Advisor
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with a strong background in medical technology and orthopedic implants.
Active Implants' leadership includes individuals like Ted Davis, who has a history of leading medical device companies, and Dr. Elliott Hershman, a seasoned orthopedic surgeon. Their combined expertise in medical technology and orthopedic implants provides a solid foundation for the company's strategic direction and product development.
- Clinical Need
-
Aspect: Very Strong
Summary: The NUsurface Meniscus Implant addresses a significant unmet need for patients with persistent knee pain post-meniscectomy.
Many patients continue to experience knee pain after meniscus surgery, with limited treatment options available. The NUsurface implant offers a less invasive alternative to total knee replacement, potentially improving quality of life for a large patient population.
- Competition
-
Aspect: Somewhat crowded
Summary: The meniscus implant market includes several established players, but NUsurface offers unique advantages.
Competitors like Stryker and Zimmer Biomet offer meniscus repair solutions. However, NUsurface's unique design, which doesn't require fixation to bone or soft tissues, and its ability to mimic natural meniscus function, may differentiate it in the market.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of the NUsurface implant involves manageable technical challenges.
Developing a synthetic meniscus implant requires expertise in biomaterials and biomechanics. Active Implants' R&D facilities in Israel and collaborations with orthopedic experts have enabled the successful development and clinical testing of the NUsurface implant.
- Patent
-
Aspect: Strong
Summary: Active Implants holds strong patents protecting the NUsurface technology.
The NUsurface implant's design and materials are protected by patents, preventing competitors from replicating the technology. This intellectual property protection supports the company's market position and potential for licensing opportunities.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding to support product development and clinical trials.
Active Implants completed the first $10 million tranche of a $40 million financing round in 2017, with contributions from LS Health Science Partners and existing investors. This funding supports ongoing clinical trials and regulatory efforts for the NUsurface implant.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The NUsurface implant is undergoing pivotal clinical trials to obtain FDA approval.
The NUsurface implant has received Breakthrough Device Designation from the FDA and is currently in pivotal trials. Positive results are essential for securing regulatory approval and subsequent commercialization in the U.S. market.
Opportunity Rollup
- Odds of Success
- 3.65
- Peak Market Share
- 4.5
- Segment CAGR
- 9.4%
- Market Segment
- Orthopedic Devices
- Market Sub Segment
- Meniscus Implants
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.67 |
| 3 | 1.57 |
| 4 | 3.15 |
| 5 | 4.50 |
Key Takeaway
Active Implants' NUsurface Meniscus Implant addresses a significant clinical need with strong market potential, supported by experienced leadership and robust funding.